This episode is a replay of a recent live webinar. For the full video version including slides, diagrams, and live Q&A, please visit the Arthramid Canine YouTube channel (https://www.youtube.com/watch?v=BOwYo_ByFAA&t=17s)

In this session, the panel examines the safety profile and practical use of 2.5% Arthramid (iPAAG) in both dogs and horses. Drawing on published research, global post‑market data, and extensive clinical experience, the discussion provides an evidence‑based overview of what veterinarians can expect when using iPAAG across different joints, patient types, and clinical scenarios.

Key discussion themes

• Canine clinical safety and outcomes
• Real‑world clinical experience from more than 2,000 canine joint injections
• Retrospective owner‑reported outcomes showing transient soreness rates of 10–15%
• Prospective study findings: majority of dogs progressing comfortably to 12 months
• Injection technique considerations, especially for elbows and hipsUse in small or tight joints, including distal phalangeal jointsInfluence of age, chronicity and body condition on expected response
• When and how concurrent therapies (PRP, corticosteroids) may be used
• Equine research and synovial response
• Overview of global equine safety data and long-term useHistology findings showing a transient, low‑grade macrophage response
• Clarification around misconceptions regarding synovial “foreign body” reactions
• Key differences between early non‑septic flares and later‑onset septic presentations
• Needle placement and imaging guidance to reduce extra‑articular deposition
• Adverse events and management strategiesReview of global post‑marketing data (>90,000 syringes), showing very low AE rates
• Differentiating septic vs non‑septic flares, and appropriate first‑line responses
• Why synovial sampling, NSAIDs, and systemic antibiotics are typically sufficient
• Avoiding unnecessary synovectomies or intra-articular aminoglycosides in non‑septic presentations
• Technique and practical considerationsBest practices for aseptic prep, needle control, and sedation/anaesthesia
• Dose considerations based on pathology severity
• Timing of rehabilitation and why adjunct modalities (laser, shockwave) should wait 4–6 weeksImportance of monitoring, follow‑up assessment, and client communication

We'd like to thank you panelists for this discussion: Dr. Courtney Campbell | Stitches Veterinary Surgery, Long Beach, CADr. Jess Gleesher | Skilo Sports Medicine, Woodstock, MDDr. Carl Maritado | MedVet Medical and Cancer Centers, Cincinnati, OHModerated by Dr. Meg Green | Technical Services Veterinarian, Contura Vet